Notice of Cipher Pharmaceuticals Inc. fiscal 2007 first quarter conference call

    First quarter financial results to be released on May 2, 2007

    Toronto Stock Exchange Symbol: DND

    MISSISSAUGA, ON, April 25 /CNW/ - Cipher Pharmaceuticals Inc. (TSX: DND),
will host a conference call on Wednesday, May 2, 2007 at 10:00 a.m. (ET) to
discuss its fiscal 2007 first quarter financial results. Cipher invites all
interested parties to participate. You can join the call by dialing
416-644-3431 or 1-800-595-8550. Please call in 15 minutes prior to the call to
secure a line. You will be put on hold until the conference call begins.
    Larry Andrews, President and CEO, will chair the call. A question and
answer session will follow, at which time the operator will direct
participants as to the correct procedure for submitting questions. A taped
replay of the conference call will be available until Wednesday, May 9, 2007
by calling 416-640-1917 or 1-877-289-8525, reference number 21228023 followed
by the number sign.
    A live audio webcast of the conference call will be available through Please connect at least 15 minutes prior to the
conference call to ensure adequate time for any software download that may be
needed to hear the webcast. An archived replay of the webcast will be
available for 360 days.

    About Cipher Pharmaceuticals Inc.
    Cipher Pharmaceuticals is a drug development company focused on
commercializing novel formulations of successful, currently marketed molecules
using advanced drug delivery technologies. Cipher's strategy is to in-license
products that incorporate proven drug delivery technologies and advance them
through the clinical development and regulatory approval stages, after which
the products are out-licensed to international partners. Because Cipher's
products are based on proven technology platforms applied to currently
marketed drugs, they are expected to have lower approval risk, shorter
development timelines and significantly lower development costs. Cipher
currently has three late-stage drugs in its pipeline. The Company's lead
compound, CIP-FENOFIBRATE, received final approval from the U.S. Food and Drug
Administration and Health Canada in the first quarter of 2006. In addition,
Cipher is developing formulations of the pain reliever tramadol (currently
under regulatory review by the FDA) and the acne treatment isotretinoin
(currently under regulatory review by the FDA).
    Cipher is listed on the Toronto Stock Exchange under the symbol 'DND' and
has approximately 24 million shares outstanding.  For more information, please

    Forward-Looking Statements
    Statements made in this news release, other than those concerning
historical financial information, may be forward-looking and therefore subject
to various risks and uncertainties. Some forward-looking statements may be
identified by words like "may", "will", "anticipate", "estimate", "expect",
"intend", or "continue" or the negative thereof or similar variations. Certain
material factors or assumptions are applied in making forward-looking
statements and actual results may differ materially from those expressed or
implied in such statements. Factors that could cause results to vary include
those identified in the Company's Annual Information Form and other filings
with Canadian securities regulatory authorities, such as the applicability of
patents and proprietary technology; possible patent litigation; regulatory
approval of products in the Company's pipeline; changes in government
regulation or regulatory approval processes; government and third-party payer
reimbursement; dependence on strategic partnerships for product candidates and
technologies, marketing and R&D services; meeting projected drug development
timelines and goals; intensifying competition; rapid technological change in
the pharmaceutical industry; anticipated future losses; the ability to access
capital to fund R&D; and the ability to attract and retain key personnel. All
forward-looking statements presented herein should be considered in
conjunction with such filings. The Company does not undertake to update any
forward-looking statements; such statements speak only as of the date made.

For further information:

For further information: Craig Armitage, Investor Relations, The Equicom
Group, (416) 815-0700 ext 278, (416) 815-0080 fax,;
Larry Andrews, President and CEO, Cipher Pharmaceuticals, (905) 602-5840 ext
24, (905) 602-0628 fax,

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890